← All trials
NCT00843050
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2009
- Primary completion
- Feb 1, 2011
- Completion date
- Aug 1, 2012
- First posted
- —
- Last posted
- —
- Enrollment
- 13
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- PiramalLead sponsor
- Meenakshi Ammal Dental College and HospitalOverall official - principal investigator
- Malabar Institute of Medical SciencesOverall official - principal investigator
- Mayo ClinicOverall official - principal investigator
- Gabrail Cancer CenterOverall official - principal investigator
- Jaslok Hospital and Research Centre, Mumbai, IndiaOverall official - principal investigator
- Tata Memorial HospitalOverall official - principal investigator
- University of WisconsinOverall official - principal investigator
- University of WashingtonOverall official - principal investigator
- Vanderbilt UniversityOverall official - principal investigator
- Rutgers UniversityOverall official - principal investigator
- Cancer Care Centers of South Texas , San AntonioOverall official - principal investigator
- University of UtahOverall official - principal investigator
- All India Institute of Medical SciencesOverall official - principal investigator
- Cancer Care Clinic and Hospital, Nagpur, IndiaOverall official - principal investigator
- Rajiv Gandhi University of Health SciencesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.